Globe says Canopy backs making testing results public 2017-02-27 06:43 ET - In the News
Also In the News (C-ACB) Aurora Cannabis Inc
Also In the News (C-CMED) CanniMed Therapeutics Inc
Also In the News (C-OGI) Organigram Holdings Inc
The Globe and Mail reports in its Saturday, Feb. 25, edition that Canopy Growth chief executive officer Bruce Linton is in favour of a system where companies would have to test their products for safety -- and make those lab results public -- to earn back the trust of patients amid a tainted cannabis scare. The Globe's Grant Robertson writes that Mr. Linton says he would have no problem producing lab results to show that the product is free of pesticides and other chemicals. Mr. Linton says he is already holding internal discussions on how to do it. The move comes after federally licensed medical marijuana companies Organigram, Canopy's Mettrum and Aurora Cannabis were caught selling products containing a dangerous banned pesticide called myclobutanil. With the industry's credibility now under fire, Saskatoon-based CanniMed Therapeutics last week pledged to make its testing results public, to show patients its products are safe. Canopy, which represents about 40 per cent of the medical market, likes the idea. Mr. Linton says: "We're supportive of that. It's all about confidence. I don't think there's any hurdles to doing it, it's just how do you do it properly?"